2026-02-24
Estrogen, Menopause, and Aging: Hormonal Mechanisms, Health Implications, and Protocol
Menopause-associated estrogen decline drives accelerated changes in cardiovascular risk, bone density, cognitive function, and metabolic health. Menopausal hormone therapy (MHT) has RCT and observational evidence supporting benefits for symptomatic relief and bone protection; cardiovascular and breast cancer risks depend on timing, type, and route of administration.
2026-02-24
GLP-1 Agonists and Aging: Metabolic Benefits, Cardiovascular Evidence, and Longevity Implications
GLP-1 receptor agonists like semaglutide have demonstrated cardiovascular and metabolic benefits beyond weight reduction. This review covers the mechanistic basis, major trial evidence, and the open questions about their role in longevity medicine.
2026-02-24
Grip Strength as a Longevity Biomarker: Evidence and Interventions
Grip strength is one of the most powerful and accessible biomarkers of biological aging, predicting cardiovascular events, hospitalization, and all-cause mortality more reliably than many clinical tests. This article covers the mechanisms, evidence, and interventions.
2026-02-24
Intermittent Fasting and Aging: Metabolic Benefits, Muscle Risk, and Evidence Review
Intermittent fasting (IF) protocols — including 16:8 time-restricted eating and 5:2 alternate-day approaches — produce modest metabolic benefits similar to matched caloric restriction. Autophagy induction is mechanistically plausible but not confirmed in humans at the cellular level during typical IF windows. Muscle mass preservation requires attention to protein timing and resistance training.
2026-02-24
Joint Health and Cartilage Support: What the Evidence Shows
Cartilage has limited self-repair capacity, but several interventions modestly slow degradation and reduce symptoms. Here is what the clinical evidence supports for joint health in aging.